AstraZeneca Breast Cancer Pill Camizestrant Fails Trial — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- AstraZeneca said Friday that camizestrant, its oral breast cancer pill, failed in the SERENA-4 pivotal trial testing it as a first-line therapy in advanced tumors.
- Camizestrant combined with another medicine did not beat standard treatment on the measure of how long patients went before their cancer progressed.
- The SERENA-4 trial enrolled patients with ER-positive, HER2-negative advanced cancer who had not previously received another systemic therapy for advanced disease.
- Camizestrant had already won accelerated U.S. approval earlier this month under the name Etcamah for patients whose tumors develop a mutation signaling emerging drug resistance.
- A successful SERENA-4 result could have opened up a much larger market for the drug beyond the narrower mutation-specific indication it currently holds.
Why it matters: The SERENA-4 failure narrows camizestrant's commercial path to the smaller drug-resistance population where it already holds accelerated FDA approval as Etcamah, cutting off the broader first-line advanced breast cancer market AstraZeneca was pursuing. For AstraZeneca's oncology pipeline, the setback caps the drug's revenue ceiling and forces the company to rely on the narrower mutation-driven indication to recoup its investment.
Ask SkimNews
